Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.33 |
| ▸ | CDC7 | O00311 | 2/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21712641 | 0.87 | CDC7 (0.38) | CDC7DBF4ROCK1NPC1RAB9A | |
| SCHEMBL21729584 | 0.85 | AAK1 (0.37) | AAK1ABCB1CDC7DBF4ROCK1 | |
| SCHEMBL28455399 | 0.84 | AAK1 (0.41) | AAK1ABCB1CDC7DBF4ROCK1 | |
| SCHEMBL21729557 | 0.84 | AAK1 (0.41) | AAK1ABCB1CDC7DBF4ROCK1 | |
| SCHEMBL21729586 | 0.84 | AAK1 (0.39) | AAK1ABCB1CDC7DBF4ROCK1 | |
| SCHEMBL21729493 | 0.82 | AAK1 (0.42) | AAK1ABCB1CDC7DBF4ROCK1 | |
| SCHEMBL28453787 | 0.82 | CDC7 (0.43) | AAK1ABCB1CDC7DBF4ROCK1 | |
| SCHEMBL21729495 | 0.82 | CDC7 (0.43) | AAK1ABCB1CDC7DBF4ROCK1 | |
| SCHEMBL28457041 | 0.82 | AAK1 (0.42) | AAK1ABCB1CDC7DBF4ROCK1 | |
| SCHEMBL28446403 | 0.81 | ABCB1 (0.37) | AAK1ABCB1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745410-B2 | Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents | ZENJI RESEARCH LABORATORIES (CN) | 2020-08-18 | — | — | US | disclosed |
| US-20200055867-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | ZENJI RESEARCH LABORATORIES (CN) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055867-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | CDC7, CDK7, CDK17 | AAK1 910/4885ABCB1 1745/4885CDC7 1/4885 |
| US-10745410-B2 | Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents | CDC7, CDK7, CDK17 | AAK1 910/4885ABCB1 1745/4885CDC7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.